Shots:
- The complete dose-finding part of P-Ib/II study assessed the safety, feasibility, and RP2D of NBTXR3 (intratumoral inj.) in 20 patients with LA (T3 to T4) or unresectable rectal cancer
- The study showed ORR after CCRT in >70% patients, 90% patients underwent total mesorectal excision (surgery); 17.6% achieved pCR; 50% receiving surgery had good tumor regression; therapy was feasible and was well tolerated at all dose levels
- Nbtxr3 is a novel, potentially first-in-class therapy designed to destroy tumors through physical cell death when activated by radiotherapy.
Click here to read full press release/ article | Ref: Businesswire | Image: Wikipedia
The post Nanobiotix Presents Results of NBTXR3 (PEP503) in P-Ib/II Study for Rectal Cancer at ASCO-GI 2021 first appeared on PharmaShots.
